The importance of plasma B-type natriuretic peptide levels in cardiovascular diseases;Plazma B-tipi natriüretik peptid düzeylerinin kardiyovasküler hastaliklardaki yeri ve önemi

Anadolu Kardiyoloji Dergisi

Volumn 5, Issue 4, 2005, Pages 305-311

  Duygu, Hamza ^a   Türk, Uǧur ^a   Zoghi, Mehdi ^a   Nalbantgil, Sanem ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acute coronary syndrome; Brain natriuretic peptide; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; ORBOFIBAN;

BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIASTOLE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; HORMONE BLOOD LEVEL; HUMAN; PROGNOSIS; REVIEW; SYSTOLE;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 29544451458     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Stein BC, Levin RI. Natriuretic peptides: physiology therapeutic potential and risk stratification in ischemic heart disease. Am Heart J 1998; 135: 914-23.
2. Cheung BM, Kumana CR. Natriuretic peptides-relevance in cardiac disease. JAMA 1998; 280: 1983-4.
3. Nagagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy. Evidence for BNP as an 'emergency' cardiac hormone against ventricular over load. J Clin Invest 1995; 96: 1280-7.
4. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet 1997; 351: 3-4.
5. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-6.
6. Yoshimura M, Yasue H, Okamura K et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with conjestive heart failure. Circulation 1993; 87: 464-9.
7. Davidson NC, Naas AA, Hanson JK, et al. Comparison of atrial natriuretic peptide, BNP and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828-31.
8. Levin ER, Gardner DG et al. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.
9. Richards AM, McDonald D, Fitzpatrick MA, et al. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J Clin Endocrinol Metab 1988; 67: 1134-9.
10. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25: 227-34.
11. Itih H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990; 86: 1690-7.
12. Dloras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 1990; 81: 1860-73.
13. Burnett JC Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984; 247: 863-6.
14. Maisel AS. B-type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. Rev Cardiovasc Med 2001; 2: 13-8.
15. Wuerz RC, Meador SA. Effects of pre-hospital medications on mortality and length of stay in CHF. Ann Emerg Med 1992; 21: 669-74.
16. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 884-8.
17. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315-21.
18. Deveraux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension 1987; 9: 97-104.
19. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440-4.
20. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting. J Am Coll Cardiol 2001; 37: 379-85.
21. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: Results from the Breathing Not Properly Multinational study. J Am Coll Cardiol. 2003; 41: 2018-21.
22. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide (BNP) predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131-8.
23. Berger R, Huelsman M, Stecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.
24. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH, CIDS studies. Eur Heart J 2000; 21: 2071-8.
25. Richards AM, Doughty R, Nicholls MG, et al. for the Australia -New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999; 99: 786-92.
26. Maeda K, Tsutamoto T, Wada A, et al. High levels of plazma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-93.
27. Isnard R, Pousset F, Trochu J, et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000; 86: 417-21.
28. Omland T, Bonarjee WS, Lie RT, et al. Neurohumoral measurements as indicators of long term prognosis after acute myocardial infarction. Am J Cardiol 1995; 76: 230-5.
29. Struthers AD, Morris AD. Screening for and treating left ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002; 359: 1430-2.
30. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting -enzyme inhibition after myocardial infarction. Lancet 1993; 341: 1109-13.
31. Mammalaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-66.
32. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-33.
33. Maisel AS, Krishnaswamy P, Koon F, et al. Utility of B-type natriuretic peptide (BNP) as a rapid, point-of-care test for screening patients undergoing echocardiography for left ventricular dysfunction. Am Heart J 2001; 141: 367-74.
34. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996; 76: 232-7.
35. Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 2000; 86: 1036-40.
36. Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142: 725-32.
37. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
38. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-type natriuretic peptide assay in differentiating conjestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9.
39. Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with conjenital heart disease. Circulation 2002; 106: 92-9.
40. Matsuo K, Nishikimi T, Yutani C, et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation 1998; 98: 2433-40.
41. Cheng VL, Krishnaswamy P, Kazanagra R, et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted with decompensated heart failure. J Am Coll Cardiol 2001; 37: 386-91.
42. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
43. Latini DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126-32.
44. Maisel AS. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 2002; 3(Suppl): S13-6.
45. Sodian R, Loebe M, Schmitt C, et al. Decreased plasma concentrations of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 2001; 38: 1942-9.
46. Nagaya N, Nishikimi T, Goto Y, et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after myocardial infarction. Am Heart J 1998; 135: 21-8.
47. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
48. Lemos JA, Morrow D, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
49. Sabatina MC, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Circulation 2002; 105: 1760-3.